Zobrazeno 1 - 5
of 5
pro vyhledávání: '"329"'
Autor:
Jennifer S. Temel, Tanya Keenan, Yi-Bin Chen, Harry VanDusen, Areej El-Jawahri, Daniel J. DeAngelo, Amir T. Fathi, Thomas W. LeBlanc, Philip C. Amrein, David P. Steensma, Lara Traeger, Richard Stone, Karen K. Ballen, Martha Wadleigh, Gregory A. Abel, Gabriela S. Hobbs
Publikováno v:
Blood. 126:2104-2104
Introduction: Older adults (≥ 60 years) with acute myeloid leukemia (AML) generally have a poor prognosis and a high rate of health care utilization including intensive care unit (ICU) admissions. While the outcomes of older patients with advanced
Autor:
Neeraj Agarwal, Jason Li, Nicole Hagner, Margaret M. Woo, Martijn P. Lolkema, Sunil Sharma, Emile E. Voest, Petronella O. Witteveen, Maria Grazia Porro, Dagmar Hess, Derek Mires, Sue-zette Valera
Publikováno v:
Blood. 118:5001-5001
Abstract 5001 Panobinostat is a potent class I/II/IV oral pan-deacetylase inhibitor which has shown promising clinical activity in patients with multiple myeloma and myelofibrosis, some with compromised renal and hepatic functions. The metabolism med
Autor:
Jana Markova, Andreas Engert, Richard Herrmann, Peter Borchmann, Rolf P. Mueller, Bernd Doerken, Michael Fuchs, Annette Pluetschow, Hans Konrad Mueller-Hermelink, Hans Theodor Eich, Volker Diehl, Lothar Kanz, Richard Greil
Publikováno v:
Blood. 114:716-716
Abstract 716 Background: There has been an ongoing debate on the best treatment for patients with early favourable Hodgkin lymphoma (HL). Open questions include the choice between combined modality treatment or chemotherapy only, the number of chemot
Autor:
John A. Liu Yin, Lars Kjeldsen, Robert Kerrin Hills, Brenda Gibson, Alan Kenneth Burnett, Donald Milligan, Ann Hunter, Archie G. Prentice, Anthony H. Goldstone, Keith Wheatley, Nigel H. Russell
Publikováno v:
Blood. 114:484-484
Abstract 484 On behalf of the NCRI AML Working Group, United Kingdom There is a general acceptance that survival in younger patients (75% relapse remains a problem. Optimisation of induction and defining the schedule and duration of post-induction ch
Autor:
Andrea Bacigalupo, Gérard Socié, Meral Beksac, Nigel H. Russell, Birte Friedrichs, Norbert Schmitz, Tapani Ruutu, Andre Tichelli
Publikováno v:
Blood. 112:451-451
In 2002, the EBMT reported on the largest prospective randomized study comparing filgrastim-mobilized peripheral blood progenitor cell (PBPC) to bone marrow (BM) transplantation (Schmitz et al. Blood 2002). Patient accrual took place between 02/95 an